GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients
GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients
OTTAWA, Ontario, May 28, 2019 /PRNewswire/ -- GBS Global Biopharma, Inc. ("GBS Global"), a Canadian-based subsidiary of GB Sciences, Inc. (GBLX), announced preclinical studies on their proprietary chronic-neuropathic...
Positioned to Increase Revenue by Approximately $5.6 Million LAS VEGAS , May 14, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) today announced it is nearing completion of $700,000 in power and water...
Increases production and ensures a continuous supply of therapeutic cannabis for Louisiana patients. LAS VEGAS, April 16, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX), a partner in GB Sciences Louisiana,...
LAS VEGAS, April 2, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announced that Dr. Dominick Monaco, GB Sciences' Director of Medical Formulations, will be a featured speaker at the Las Vegas Cannabis...
LAS VEGAS, March 28, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) today announced results from a new study that shows only three chemical varieties of cannabis were sold in the Nevada dispensaries between...
With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana. LAS VEGAS,...
With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana. LAS VEGAS,...
Expedites innovative cannabinoid medicine program, covering 60 disease and health conditions including Parkinson's Disease, neuropathic pain and cardiac hypertrophy LAS VEGAS , March 19, 2019 /PRNewswire/...
LSU AgCenter issued the following statement on Friday, March 8th. LAS VEGAS , March 12, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announces that the Louisiana State University Agricultural Center...
To help our patients, GB Sciences is creating a pipeline for the development of novel medicines based on our own patent-pending formulations of chemicals extracted from the Cannabis plant. Through its wholly-owned subsidiary, Growblox Life Sciences, LLC, GB Sciences has now filed three provisional patent applications on new therapies that are complex mixtures of compounds derived from cannabis, and it has licensed an additional approved patent.
GB Sciences partners with universities and contract research organizations (CROs), who bring both expertise and infrastructure at a reasonable cost to our program. Our end goal is not to take these novel formulations to market ourselves, because we know our limitations. Our goal is to be the perfect partner to those companies with greater resources and experience in the marketing and distribution of medications worldwide.
The GB Sciences Scientific Advisory Board provides oversight for product development within GB Sciences’ intellectual property portfolio.
GB Sciences has several advantages over both pharmaceutical companies and academic researchers when it comes to the discovery and validation of new drug formulations from cannabis-derived compounds.